Zymeworks
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 E 4th Ave Ste 800, Vancouver, Britis...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$81.3 MillionStock Symbol
ZYMEIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
1
1
1
1
About Zymeworks
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.Explore more
Zymeworks Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Zymeworks launches new products
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Click to see if Zymeworks had a recent Job posting/layoffs
Check out if Zymeworks is spiking on competitors!
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Zymeworks has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zymeworks is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$22.3M
2015
Multiple Rounds
$34.4M
2016
Series A
$61.5M
2017
Stock Offering
$63.6M
2018
Stock Offering
$97.8M
2019
Stock Offering
$201.3M
2020
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
See more technologies
Most Recent Scoops
Open Position
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Research & Development
Person-Based
Pharmaceuticals
Zymeworks News & Media
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) GynaecologicalZymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminatedZymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsShrinal Inamdar - VP of Investor RelationsKenneth Galbraith -...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Sign Up For FreeTo access detailed company insights
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.... Read More
